Stephen Paul Fortmann
Curriculum Vitae

Current Positions: Senior Investigator and Assistant Program Director
Kaiser Permanente Center for Health Research
Kaiser Permanente Northwest
3800 North Interstate Avenue
Portland, Oregon 97227-1098, USA

Voice: +1 503-335-2459; Fax: +1 503-335-2428
EM: Stephen.Fortmann@kpchr.org
Web: http://www.kpchr.org/

C. F. Rehnborg Professor in Disease Prevention (Emeritus)
Stanford University School of Medicine

Academic History

1. Education

1966-1970	Stanford University, A.B. (Biology)
1970-1974	University of California, San Francisco, M.D.

2. Postdoctoral and Residency Training

Santa Clara Valley Medical Center, San Jose, California

1974-1975	Internship in Medicine and Pediatrics
1975-1977	Residency in Medicine

Stanford University School of Medicine, Stanford, California

1977-1979	Research Fellow in Cardiovascular Disease Epidemiology and Prevention, Stanford Heart Disease Prevention Program
1977-1979	Robert Wood Johnson Clinical Scholar
1978	Fellow, Fourth U.S. Ten-Day Seminar on Cardiovascular Disease Epidemiology, American Heart Association

3. Board Certification and Licensure

1975	National Board of Medical Examiners
1975–	Physician and Surgeon Certificate, Medical Board of California (G29702) [Retired/Inactive status, GFE29702, 2010–]
1977	American Board of Internal Medicine

4. Research (Current Support in Boldface):

1983–1986	PI: *Effects of Weight Loss on Ambulatory Blood Pressure in Man*; National Heart, Lung, and Blood Institute, (HL 31138)
1983–1992	Director and Co-PI: *Stanford Five-City Multifactor Risk Reduction Project*; National Heart, Lung, and Blood Institute (HL 21906)
1984–1990	PI: *Self-Help Smoking Cessation and Maintenance Study*; National Cancer Institute (CA 39303)

1988–1994	PI: *A Population-based Study of Cessation in Heavy Smokers*; National Heart, Lung, and Blood Institute (HL 39770)
1990–1991	PI: *Smoking Cessation for American Indians* (subcontract from Northern California Cancer Center)
1990–1991	PI: *Reducing the Illegal Sale of Tobacco to Minors*; Thrasher Research Fund
1991–1994	Co-PI: *Relating Tobacco Access and Consumption Among Youth*; California Tobacco-Related Disease Research Program (2RT0227)
1991–1997	PI: *Cardiovascular Disease Nutrition Education in Low Literate Adults*; National Heart, Lung, and Blood Institute (HL 46782)
1992–1997	PI: *Stanford Five-City Multifactor Risk Reduction Project*; National Heart, Lung, and Blood Institute (HL 21906)
1992–1996	PI: *Nicotine Patch Treatment for Smoking Relapse Prevention*; National Heart, Lung, and Blood Institute (HL 47219)
1992–2009	PI: *Cardiovascular Disease Prevention Training Program*; National Heart, Lung, and Blood Institute (HL 007034)
1994–1995	PI: *A Placebo-controlled Study Assessing the Safety and Relative Efficacy of High Dose Nicoderm*; ALZA Corporation
1995–2000	PI: *High Dose Nicotine Replacement for Heavy Smokers*; National Cancer Institute (CA 68968)
1995–2000	PI: *Smokeless Tobacco: Nicotine Patch Self-Help Treatment*, National Cancer Institute (CA 64285)
1997–1998	PI: *A 54-Week Open Label Assessment of the Safety and Efficacy of Atorvastatin*, Parke-Davis/Pfizer
1997–2000	PI: *Evaluation of the California Wellness Foundation Violence Prevention Initiative*, California Wellness Foundation
1997–2001	PI: *Policy Studies on Limiting Tobacco Marketing to Youth*, National Cancer Institute (CA 67850)
1997–2000	PI: *Environmental Influences on Adolescent Drinking*: Community Support for Policy Solutions, Robert Wood Johnson Foundation
1997–2000	Co-PI: *Nicotine Replacement and Paroxetine for Smoking Cessation*, California Tobacco-Related Disease Research Program (6RT-0041)
1998–2001	PI: *Reducing Provision of Tobacco to Minors from Social Sources*, California Tobacco-Related Disease Research Program (7RT-0156)
1998–2001	Co-PI: *Effects of Selegiline on Craving for Nicotine* (Killen) California Tobacco-Related Disease Research Program (7RT-0094)
2000–2003	PI: *Tests of the Tobacco Industry's Youth Smoking Prevention Ads*, California Tobacco-Related Disease Research Program (9RT-0138)
2000-2006	PI: *Genetic Epidemiology of Cardiovascular Disease and Healthy Aging*; a component of the Donald W. Reynolds Cardiovascular Clinical Research Center at Stanford University (M. Hlatky, PI)
2000–2004	Co-investigator: *Improving Adherence for Dyslipidemia and Anticoagulation* (Rudd), National Heart, Lung, and Blood Institute (HL66799)
2001–2004	Co-investigator: *Neighborhood Level Influences on All-Cause Mortality* (Winkleby) NIEHS/NHLBI (HL67731)

2001–2005	Co-PI: *Maintenance Treatment for Smoking Cessation* (Killen), National Cancer Institute (CA90300)
2002–2014	**Investigator (PI 2002-2010): *Impact of Retail Tobacco Advertising on Youth Smoking* (Henriksen), National Cancer Institute (CA067850)**
2002–2005	Co-investigator: *National Trends in Outpatient Quality Indicators* (Stafford), Agency for Healthcare Research and Quality (HS11313)
2003–2007	Co-PI: *Behavioral Maintenance Treatment for Smoking Cessation* (Killen), National Institute on Drug Abuse (DA01744)
2004–2006	PI: *The Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia* (SEACOAST Study), Kos Pharmaceuticals, Inc.
2005–2009	Co-PI: *Selegiline Patch for Treatment of Nicotine Dependence* (Killen), National Institute on Drug Abuse
2005-2007	Investigator, *Effects of Outlet/Ad Density on Teen Smoking* (Henriksen), California Tobacco-Related Disease Research Program
2006–2009	Investigator, *Whole Genome Association for Early Coronary Artery Disease and Related Phenotypes* (Quertermous), National Heart, Lung, and Blood Institute (HL087647)
2008–2011	**Investigator (Co-PI 2008-2010), *Association of Outlet Density with Smoking and Pack Price* (Henriksen); California Tobacco-Related Disease Research Program (17RT-0152)**
2009–2011	**Investigator, *Modeling and Mapping Changes in Tobacco Outlet Density* (Henriksen); California Tobacco-Related Disease Research Program (18RT-0101)**
2009–2013	**Investigator, *Identifying Disparities in Type 2 Diabetes Among Asian Americans: The Pan Asian Cohort Study (PACS)*, (Palaniappan), National Institute of Diabetes and Digestive and Kidney Diseases (DK081371)**

Employment History

Stanford University School of Medicine, Stanford, California (1979–2010)

1979–1982	Physician Specialist and Clinical Instructor, Department of Medicine
1979–1982	Director of Community Studies, Stanford Heart Disease Prevention Program
1983–1987	Co-Director, Cardiovascular Disease Epidemiology and Prevention Training Program
1983–1988	Associate Director, Stanford Center for Research in Disease Prevention
1983–1989	Assistant Professor of Medicine
	Assistant Professor of Epidemiology (by courtesy)
1983–1989	Co-Director, Stanford Preventive Medicine Clinic
1987–2010	Director, Cardiovascular Disease Epidemiology and Prevention Training Program, PI: Cardiovascular Disease Prevention Training

	Program, National Heart, Lung, and Blood Institute (5 T32 HL 007034; 1987–2011)
1988–1997	Deputy Director, Stanford Center for Research in Disease Prevention
1988–1996	Head, Section on Clinical Epidemiology and Disease Prevention, Division of General Internal Medicine
1990–2010	Director, Preventive Cardiology Clinic, Division of Cardiovascular Medicine
1990–1995	Associate Professor of Medicine (Clinical)
	Associate Professor of Health Research and Policy (Epidemiology) (by courtesy)
1995–1999	Associate Professor of Medicine
	Associate Professor of Health Research and Policy (Epidemiology) (by courtesy)
1998–2010	Director, Stanford Prevention Research Center (formerly Center for Research in Disease Prevention)
1999–2010	C. F. Rehnborg Professor in Disease Prevention, Department of Medicine
1999–2010	Professor of Medicine (General Internal Medicine)
1999–2010	Professor of Health Research and Policy (Epidemiology) (by courtesy)
2010–	C. F. Rehnborg Professor in Disease Prevention in the School of Medicine (Emeritus)

Kaiser Permanente Center for Health Research (2010–)

2010–	Senior Investigator and Assistant Program Director

Public and Professional Service

Committees

International

1982–1985	Chairman, Steering Committee of the World Health Organization MONICA Project
1993–1997	Organizing Committee of the Fourth International Conference on Preventive Cardiology
1993–1998	Leader, Main Results Writing Group, World Health Organization MONICA Project

National/Regional

1979–1982	Member, Criteria and Methods Committee, American Heart Association Council on Epidemiology and Prevention
1980–1990	Coordinating Committee for Community Demonstration Studies, National Heart, Lung, and Blood Institute
1985–1988	Chairman, Criteria and Methods Committee, American Heart Association Council on Epidemiology and Prevention

1985–1988	Consultant, National Center for Health Statistics (advised on development of the tenth revision of the International Classification of Diseases).
1987–2002	Member, Policy Board, Atherosclerosis Risk in Communities Study, National Heart, Lung, and Blood Institute
1988–1989	California Chronic and Sentinel Disease Surveillance Program Task Force; Department of Health Services, State of California
1988–1990	Epidemiology Advisory Group, American Cancer Society, California Division
1988–1990	Executive Committee, American Heart Association Council on Epidemiology
1989	Ad hoc Committee on Hypertension Prevention and Control, Department of Health Services, State of California
1989	Tobacco Research Working Group, Northern California Cancer Center
1989–1990	Scientific Advisory Committee: Detection, Prevention, and Education Program, Northern California Cancer Center
1991–1992	Research Committee, California Affiliate of the American Heart Association
1991–1992	Program Committee, American Heart Association Council on Epidemiology and Prevention
1992–1994	Chairman, Program Committee, American Heart Association Council on Epidemiology and Prevention
1992–1994	Vice–Chairman, American Heart Association Council on Epidemiology and Prevention
1994–1996	Chairman, American Heart Association Council on Epidemiology and Prevention
1996	Chairman, Special Emphasis Panel on Cardiovascular Disease Surveillance, National Heart, Lung, and Blood Institute
1996–2006	Member, Special Ad Hoc Working Group for the Women's Health Initiative of the Advisory Committee on Research on Women's Health, Office on Research on Women's Health, Office of the Director, National Institutes of Health.
1996–	Member, Research Committee, California Affiliate of the American Heart Association
1997	Member, Behavioral Science, Epidemiology, and Prevention Review Committee, American Heart Association National Center
1998–2001	Chair, Committee on Epidemiologic Statistics, American Heart Association, Council on Epidemiology and Prevention
1999	Member, Planning Committee, Conference on Cardiovascular Disease Trends, National Heart, Lung, and Blood Institute
1999–2001	Member and Vice-Chair, Population Science Committee, American Heart Association National Center
2001	Member, Task Force on the Prevention of Cardiovascular Disease, National Heart, Lung, and Blood Institute
2001–2003	Chair, Population Science Committee, American Heart Association National Center

2001–2003	Member, Science Advisory and Coordinating Committee, American Heart Association National Center
2002	Member, Program Committee, "CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Application to Clinical and Public Health Practice;" American Heart Association and Centers for Disease Control and Prevention
2002	Member, Program Committee, "Workshop on Myocardial Infarction Criteria;" American Heart Association, National Heart, Lung, and Blood Institute, and Centers for Disease Control and Prevention, 28-29 May 2002
2002	Chair, Protocol Review Committee, Trial of Activity for Adolescent Girls (TAAG), National Heart, Lung, and Blood Institute, 18 July 2002
2003–2006	Chair, Data Safety and Monitoring Board, Trial of Activity for Adolescent Girls (TAAG), National Heart, Lung, and Blood Institute
2010–2013	Member, Cardiovascular and Sleep Epidemiology Study Section, National Institutes of Health
2010–2015	Member, Data Safety and Monitoring Board, **E**arly **A**dult **R**eduction of Weight Through **L**ifest**Y**le Intervention (EARLY) Trials, National Heart, Lung, and Blood Institute

University

1996–1997	Member, Advisory Panel on Investment Responsibility
1997–1998	Chair, Advisory Panel on Investment Responsibility
1997–1998	Member, Special Committee on Investment Responsibility, Board of Trustees (ex officio)
2002–2006	Senator, University Faculty Senate (elected)
2003–2006	Member, Committee on Academic Computing and Information Systems, University Senate
2004–2006	Member, Systems Governance Group, Office of the Vice President for Business Affairs
2006–2008	Member, Sustainability Working Group
2009–2010	Affiliated Faculty, Woods Institute on the Environment

School of Medicine

1996–1997	Clinical Trials Center Working Group
1996	Research Sub-committee, LCME Self-Study
2001–2002	Clinical Research Task Force
2003–2007	Executive Committee, Stanford Cardiovascular Institute
2007–2009	Steering Committee, Stanford Cardiovascular Institute

Department of Medicine

1988–2002	Executive Committee, Division of General Internal Medicine
1988–1995	Chair, Medical Service Credentials Committee
1988–1995	Medical Service Steering Committee
1997–2007	Department of Medicine Leadership Group

1997–2009	Department of Medicine Division Chiefs
2001	Chair, Ad hoc Committee on the Operating Budget

Editorships:

1980–1984	Area Editor (Epidemiology), *Behavioral Medicine Abstracts*
1996–1998	Member, Editorial Board, *Cardiovascular Risk Factors: An International Journal*.
2006–	Member, Editorial Board, *Current Cardiovascular Risk Reports*

Reviewer:

American Journal of Epidemiology
American Journal of Public Health
Annals of Internal Medicine
Circulation
Journal of the American Medical Association
New England Journal of Medicine
Preventive Medicine

Honors and Awards

Honors:

2005	Joseph E. Stokes, III, M.D., Preventive Cardiology Award, American Society for Preventive Cardiology
2005	Institute of Medicine, National Academies of Science (elected)

Fellowships:

1983	Fellow, Society for Behavioral Medicine
1984	Fellow, American Heart Association (Council on Epidemiology and Prevention)
1987	Fellow, American College of Physicians
1988	Fellow, American College of Epidemiology

Memberships:

1968–	American Association for the Advancement of Science
1977–	American College of Physicians
1978–	American Public Health Association
1978–	American Heart Association Council on Epidemiology and Prevention
1979–	Society for Epidemiologic Research
1982–	Society for General Internal Medicine
1982–	Society for Behavioral Medicine
1983–2002	American Federation for Medical Research

2000– Society for Research on Nicotine and Tobacco
2009– Society for Clinical and Translational Science

Major Invited Papers and Addresses (selected from a total of 27)

Fourth International Conference on Preventive Cardiology, Montreal, Canada, 2 July 1997
Are Preventive Efforts Effective in Populations with Low Socio-economic Status?

American Heart Association 70th Scientific Sessions, Orlando, FL, 9 November 1997
Measuring Non-traditional Risk Factors: How Much Does It Add?

National Conference on Cardiovascular Disease Prevention: Meeting the Healthy People 2010 Objectives for Cardiovascular Health. National Heart, Lung, and Blood Institute, Bethesda, MD; 27-29 September 1999.
Trends in Implementation of Population-wide Interventions to Promote Healthy Lifestyles

American Heart Association 72nd Scientific Sessions, Atlanta, GA; 7-10 November 1999; Program on Motivation and Adherence for Cardiovascular Risk Factor Reduction
Smoking Cessation Interventions

Community Prevention Research in Women's Health Conference. Centers for Disease Control and Prevention and the National Heart, Lung, and Blood Institute, Bethesda, MD, 26-27 October 2000
Cardiovascular Disease Studies: Analysis and Discussion

American Heart Association 74th Scientific Sessions, Anaheim, CA, 14 November 2001; Beyond Statins, Beta-Blockers, and ACE Inhibitors: Added Benefits of Lifestyle Modifications on Coronary Risk Reduction
Smoking Cessation

Workshop on Criteria for Acute Myocardial Infarction for Epidemiological Studies; American Heart Association Council on Epidemiology and Prevention and National Heart, Lung, and Blood Institute; Airlie Conference Center, Virginia; 28–29 May 2002
Criteria Used in the U.S. Community CVD Prevention Studies

Scholarly Publications

1. Peer-reviewed articles

1. Williams PT, **Fortmann SP**, Farquhar JW, Varady A, Mellen S. A comparison of statistical methods for evaluating risk factor changes in community-based studies: an example from the Stanford Three Community Study. *J Chron Dis* 1981;34:565-571.
2. **Fortmann SP**, Marcuson R, Bitter PH, Haskell WL. A comparison of the Sphygmetrics SR-2 automatic blood pressure recorder to the mercury sphygmomanometer in population studies. *Am J Epidemiol* 1981;114:836-844.
3. **Fortmann SP**, Williams PT, Hulley SB, Haskell WL, Farquhar JW. Effect of health education on dietary behavior: The Stanford Three Community Study. *Am J Clin Nutr* 1981;34:2030-2038.
4. **Fortmann SP**, Williams PT, Hulley SB, Maccoby N, Farquhar JW. Does dietary health education reach only the privileged? An answer from the Stanford Three Community Study. *Circulation* 1982;66:77-82.
5. Taylor CB, **Fortmann SP**. Essential hypertension. Psychosomatic illness review: No. 9 in a series. *Psychosomatics* 1983;24:433-448.
6. **Fortmann SP**, Haskell WL, Vranizan K, Brown BW. The association of blood pressure and dietary alcohol: differences by age, sex, and estrogen use. *Am J Epidemiol* 1983;118:497-507.
7. Gillum RF, **Fortmann SP**, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. *Am Heart J* 1984;108:150-8.
8. **Fortmann SP**, Rogers T, Haskell WL, Solomon DS, Vranizan K, Farquhar JW. Indirect measures of cigarette use: expired air carbon monoxide vs. plasma thiocyanate. *Prev Med* 1984;13:127-34.
9. Jacob RG, **Fortmann SP**, Kraemer HC, Farquhar JW, Agras WS. Combining behavioral treatments to reduce blood pressure: a controlled outcome study. *Behavior Modification* 1985;9:32-54.
10. Sallis JF, Haskell WL, Wood PD, **Fortmann SP**, Rogers T, Blair SN, Paffenbarger RS. Physical activity assessment methodology in the Five-City Project. *Am J Epidemiol* 1985;121:91-106. [PMID: 3964995]
11. **Fortmann SP**, Sallis JF, Magnus PM, Farquhar JW. Attitudes and practices of physicians regarding hypertension and smoking: The Stanford Five-City Project. *Prev Med* 1985;14:70-80.
12. Sallis JF, Flora JA, **Fortmann SP**, Taylor CB, Maccoby N. Mediated smoking cessation programs in the Stanford Five-City Project. *Addictive Behaviors* 1985;10:441-443.
13. Farquhar JW, **Fortmann SP**, Maccoby N, Haskell WL, Williams PT, Flora JA, Taylor CB, Brown BW, Solomon DS, Hulley SB. The Stanford Five-City Project: design and methods. *Am J Epidemiol* 1985; 122:323-34.
14. Sallis JF, Haskell WL, Wood PD, **Fortmann SP**, Vranizan KM. Vigorous physical activity and cardiovascular risk factors in young adults. *J Chron Dis* 1986;39:115-120.

15. **Fortmann SP**, Haskell WL, Williams PT, Varady AN, Hulley SB, Farquhar JW. Community surveillance of cardiovascular diseases in the Stanford Five-City Project: Methods and initial experience. *Am J Epidemiol* 1986;123:656-69.

16. Rudd P, Price MG, Graham LE, Beilstein BA, Tarbell S, Bacchetti P, **Fortmann SP**. Consequences of worksite hypertension screening. Differential changes in psychosocial function. *The American Journal of Medicine* 1986;80:853-860.

17. **Fortmann SP**, Haskell WL, Rennert MP, Williams PT, Farquhar JW. Changes in plasma high-density lipoprotein cholesterol after changes in cigarette use. *Am J Epidemiol* 1986;124:706-710.

18. Sallis JF, Haskell WL, **Fortmann SP**, Wood PD, Vranizan KM. Moderate intensity physical activity and cardiovascular risk factors: The Stanford Five-City Project. *Prev Med* 1986;15:561-568.

19. Sallis JF, Haskell WL, **Fortmann SP**, Vranizan KM, Taylor CB, Solomon DS. Predictors of adoption and maintenance of physical activity in a community sample. *Prev Med* 1986;15:331-341.

20. Sallis JF, Hill RD, Killen JD, Telch MJ, Flora JA, Girard J, Taylor CB, **Fortmann SP**. Efficacy of self-help behavior modification materials in smoking cessation. *Am J Prev Med* 1986;2:342-344.

21. Altman GA, Flora JA, **Fortmann SP**, Farquhar JW. The cost-effectiveness of three smoking cessation programs. *Am J Public Health* 1987;77: 162-165.

22. Maron DJ, **Fortmann SP**. Nicotine yield and measures of cigarette smoke exposure in a large population: Are lower-yield cigarettes safer? *Am J Public Health* 1987;77:546-549.

23. King AC, Flora JA, **Fortmann SP**, Taylor CB. Smokers' challenge: Immediate and long-term findings of a community smoking cessation contest. *Am J Public Health* 1987;77:1340-1341.

24. Williams PT, **Fortmann SP**, Terry RB, Garay SC, Vranizan KM, Ellsworth N, Wood PD. Associations of dietary fat, regional adiposity, and blood pressure in men. *JAMA* 1987;257:3251-3256.

25. Rudd P, Price MG, Graham LE, Beilstein BA, Tarbell SJH, Bachetti P, **Fortmann SP**. Consequences of worksite hypertension screening: Changes in absenteeism. *Hypertension* 1987;10:425-436.

26. Principal Investigators of the MONICA Project WHO MONICA Project: Geographic variation in mortality from cardiovascular diseases. Baseline data on selected population characteristics and cardiovascular mortality. *World Health Statistics Quarterly* 1987;40:171-184.

27. WHO MONICA Project Principal Investigators (prepared by Tunstall-Pedoe, H). The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international collaboration. *J Clin Epidemiol* 1988;41:105-114.

28. **Fortmann SP**, Haskell WL, Wood PD. Effects of weight loss on clinic and ambulatory blood pressure in normotensive men. *Am J Cardiol* 1988;62:89-93.

29. **Fortmann SP**, Killen JD, Telch MJ, Newman B. Minimal contact treatment for smoking cessation: a placebo-controlled trial of nicotine polacrilex and self-directed relapse prevention. *JAMA* 1988; 260:1575-1580.

30. Killen JD, **Fortmann SP**, Telch MJ, Newman B. Are heavy smokers different from light smokers? A comparison after 48 hours without cigarettes. *JAMA* 1988; 260:1581-1585.

31. Wood PD, Haskell WL, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko RS, **Fortmann SP**, Albers JJ, Vranizan KM, Ellsworth NM, Terry RB, Haskell WL. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. *N Engl J Med* 1988; 319:1173-9.

32. The WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. *World Health Stat Q* 1988;41:115-140.

33. Winkleby MA, **Fortmann SP**, Barrett DC. Social class disparities in risk factors for disease: eight-year prevalence patterns by level of education. *Prev Med* 1990;19:1-12.

34. Killen JD, **Fortmann SP**, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. *J Consult Clin Psych* 1990;58:85-92.

35. Albright CL, Flora JA, **Fortmann SP**. Restaurant menu labeling: Impact of nutrition information on entree sales and patron attitudes. *Health Education Quarterly [now Health Education & Behavior]*, 1990;17:157-167. [PMID 2347693]

36. Farquhar JW, **Fortmann SP**, Flora JA, Taylor CB, Haskell WL, Williams PT, Maccoby N, Wood PD. Effects of community-wide education on cardiovascular disease risk factors. The Stanford Five-City Project *JAMA* 1990;264:359-365.

37. Killen JD, **Fortmann SP**, Newman B. Weight change among participants in a large sample minimal contact smoking relapse prevention trial. *Addictive Behaviors*, 1990;15:323-332.

38. **Fortmann SP**, Winkleby MA, Flora JA, Haskell WL, Taylor CB. Effect of long-term community health education on blood pressure and hypertension control: The Stanford Five-City Project. *Am J Epidemiol*, 1990;132:629-646.

39. Jackson C, Winkleby M, Flora J, **Fortmann SP**. Use of educational resources for cardiovascular risk reduction in the Stanford Five-City Project. *Am J Prev Med*. 1991;7:82-88.

40. Taylor CB, **Fortmann SP**, Flora JA, Kayman S, Barrett DC, Jatulis DE, Farquhar JW. Effect of long-term community health education on body mass index: The Five-City Project. *Am J Epidemiol* 1991;134:235-249.

41. Killen JD, **Fortmann SP**, Newman B, Varady A. Prospective study of factors influencing the development of craving associated with smoking cessation. *Psychopharm*, 1991;105:191-196.

42. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. *JAMA*, 1991;266:3133-3138.

43. Frank E, Winkleby MA, Altman DG, Rockhill B, **Fortmann SP**. Predictors of physicians' smoking cessation advice. *JAMA* 1991;266:3139-3144.

44. Jackson C, Jatulis DE, **Fortmann SP**. The behavioral risk factor survey and the Stanford Five-City Project Survey: A comparison of cardiovascular risk behavior estimates. *Am J Public Health*, 1992;82:412-416.

45. Hyman DJ, Barrett DC, **Fortmann SP**. The effect of minor illness on serum cholesterol. *Am J Prev Med,* 1992;8:100-103.

46. Hyman DJ, Maibach EW, Flora JA, **Fortmann SP**. Cholesterol treatment practices of primary care physicians. *Public Health Reports* 1992;107:441-448.

47. Winkleby MA, Jatulis DE, Frank E, **Fortmann SP**. Socioeconomic status and health: Comparing the contributions of education, income, and occupation to cardiovascular disease risk factors. *Am J Public Health* 1992; 82:816-820.

48. Albright CL, Farquhar JW, **Fortmann SP**, Sachs DPL, Owens D, Gottlieb L, Stratos GA, Bergen MR, Skeff KM. Impact of a clinical preventive medicine curriculum for primary care faculty: Results of a dissemination model. *Prev Med* 1992;21:419-435.

49. Frank E, Winkleby MA, Rockhill B, **Fortmann SP**, Farquhar JW. Improved cholesterol-related knowledge and behavior and plasma cholesterol levels in adults during the 1980s. *JAMA* 1992;268:1566-1572.

50. Killen JD, **Fortmann SP**, Kraemer HC, Varady A, Newman B. Who will relapse? Symptoms of nicotine dependence predict long-term relapse following smoking cessation. *J Consult Clin Psych* 1992;60:797-801.

51. Winkleby MA, Rockhill B, Jatulis D, **Fortmann SP**. The medical origins of homelessness. *Am J Public Health* 1992;82:1394-1398.

52. Altman DG, Linzer J, Kropp R, Descheemaeker N, Feighery E, **Fortmann SP**. Policy alternatives for reducing sales to minors: Results from a national survey of retail chain and franchise stores. *J Public Health Policy* 1992; 13:318-331.

53. Winkleby MA, **Fortmann SP**, Rockhill B. Changes in cardiovascular disease risk factors by educational level: The Stanford Five-City Project. *Prev Med* 1992;21:592-601.

54. **Fortmann SP**, Taylor CB, Flora JA, Jatulis DE. Changes in adult cigarette smoking prevalence after five years of community health education: The Stanford Five-City Project. *Am J Epidemiol* 1993;137:82-96.

55. Frank E, Winkleby MA, **Fortmann SP**, Farquhar JW. Cardiovascular disease risk factors: Improvements in knowledge and behavior in the 1980s. *Am J Public Health* 1993;83:590-593.

56. Winkleby MA, **Fortmann SP**. Cigarette smoking trends in adolescents and young adults: The Stanford Five-City Project. *Prev Med* 1993;22:325-334.

57. Frank E, Winkleby MA, **Fortmann SP**, Rockhill B, Farquhar JW. Improvements in cholesterol-related knowledge and behavior and plasma cholesterol levels in youths during the 1980s. *Am J Public Health* 1993;9:168-174.

58. **Fortmann SP**, Taylor CB, Flora JA, Winkleby MA. Effect of community health education on plasma cholesterol levels and diet: The Stanford Five-City Project. *Am J Epidemiol* 1993;137:1039-1055.

59. Williams EL, Winkleby MA, **Fortmann SP**. Changes in coronary heart disease risk factors in the 1980's: Evidence of a male/female crossover effect with age. *Am J Epidemiol* 1993;137:1056-1067.

60. Frank E, **Fortmann SP**. The effects of smoking cessation on cardiovascular disease risk. *Cardiovascular Risk Factors* 1993;3:253-259.

61. Winkleby MA, **Fortmann SP**, Rockhill B. Health-related risk factors in a sample of Hispanics and whites matched on sociodemographic characteristics. The Stanford Five-City Project. *Am J Epidemiol* 1993;137:1365-1375.

62. Jarvik M, Killen JD, Varady A, **Fortmann SP**. The favorite cigarette of the day. *J Behavioral Med* 1993;16:413-422..

63. Frank E, Winkleby MA, **Fortmann SP**, Rockhill B, Farquhar JW. Improvements in cholesterol-related knowledge, behavior, and plasma cholesterol levels in youths during the 1980s. *Am J Prev Med* 1993;9:168-174.

64. Winkleby MA, **Fortmann SP**, Rockhill B. Health-related risk factors in a sample of Hispanics and whites matched on sociodemographic characteristics: The Stanford Five-City Project. *Am J Epidemiol* 1993;137:1365-1375.

65. Young DR, Haskell WL, Jatulis DE, **Fortmann SP**. Associations between changes in physical activity and risk factors for coronary heart disease in a community-based sample of men and women: The Stanford Five-City Project. *Am J Epidemiol* 1993;138:205-216.

66. Tribble DL, Giuliano LJ, **Fortmann SP**. Reduced plasma ascorbic acid concentrations in nonsmokers regularly exposed to environmental tobacco smoke. *Am J Clin Nutr* 1993;58:886-890.

67. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine-replacement therapy for patients with coronary artery disease. *Arch Intern Med* 1994;154:989-995.

68. **Fortmann SP**, Killen JD. Who shall quit? Comparison of volunteer and population-based recruitment in two minimal-contact smoking cessation studies. *Am J Epidemiol* 1994;140:39-51.

69. WHO MONICA Project, Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates and case fatality in 38 populations from 21 countries in 4 continents. *Circulation* 1994; 90:583-612.

70. Jackson C, **Fortmann SP**, Flora J, Melton R, Snider JP, Littlefield D. The capacity-building approach to intervention maintenance implemented by the Stanford Five-City Project. *Health Educ Res* 1994; 9:385-396.

71. Killen JD, **Fortmann SP**. The role of nicotine dependence in smoking relapse: Results from a prospective study using population-based recruitment methodology. *Int J Behav Med* 1994; 1:320-334.

72. Winkleby MA, Albright CL, Howard-Pitney B, Lin J, **Fortmann SP**. Hispanic/white differences in dietary intake among low educated adults and children. *Prev Med* 1994; 23:465-473.

73. Taylor CB, Jatulis DE, **Fortmann SP**, Kraemer HC. Weight variability effects: a prospective analysis from the Stanford Five-City Project. *Am J Epidemiol* 1995; 141:461-465.

74. **Fortmann SP**, Killen JK. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. *J Consult Clin Psych* 1995; 63:460-468.

75. Wild SH, Laws A, **Fortmann SP**, Varady AN, Byrne CD. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. *Ann Epidemiol* 1995; 5:432-439

76. Winkleby MA, Schooler C, Kraemer HC, Lin J, **Fortmann SP**. Hispanic versus White smoking patterns by sex and level of education. *Am J Epidemiol* 1995; 142:410-418.

77. **Fortmann SP**, Flora JA, Winkleby MA, Schooler C, Taylor CB, Farquhar JW. Community intervention trials: Reflection on the Stanford Five-City Project Experience. *Am J Epidemiol* 1995; 142:576-86.

78. Young DR, Haskell WL, Taylor CB, **Fortmann SP**. Effect of community health education on physical activity knowledge, attitudes, and behavior: The Stanford Five-City Project. *Am J Epidemiol* 1996; 144:264-274.

79. Gardner CD, **Fortmann SP**, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA* 1996; 276; 875-881.

80. Killen JD, **Fortmann SP**, Kraemer HC, Varady AN, Davis L, Newman, B. Interactive effects of depression symptoms, nicotine dependence and weight change on late smoking relapse. *J Consult Clinical Psychol* 1996; 64:1060-1067.

81. Oka RK, **Fortmann SP**, Varady AN. Differences in treatment of acute myocardial infarction by sex, age and other factors: the Stanford Five-City Project. *Am J Cardiol* 1996; 78:861-865.

82. Winkleby MA, Taylor CB, Jatulis D, **Fortmann SP**. Long-term effects of a cardiovascular disease prevention trial: the Stanford Five-City Project. *Am J Public Health* 1996; 86:1773-1779.

83. Winkleby MA, Kraemer HC, Lin J, Jatulis D, **Fortmann SP**. Sociodemographic influences on Hispanic-White differences in blood pressure: The Stanford Five-City Project. *Public Health Reports* 1996; 111: 30-32.

84. Wild SH, **Fortmann SP**, Marcovina SM. A prospective case-control study of lipoprotein (a) levels and apo (a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arterioscler Throm Vasc Biol* 1997; 17:239-245

85. Killen JD, **Fortmann SP**. Craving is associated with smoking relapse: findings from three prospective studies. *Exp Clin Psychopharm* 1997; 2: 137-142.

86. Killen JD, **Fortmann SP**, Davis L, Varady A. Nicotine patch and self-help video for cigarette smoking cessation. *J Consult Clin Psych* 1997; 65: 663-672.

87. Albright CL, Bruce B, Howard-Pitney B, Winkleby MA, **Fortmann SP**. Development of a curriculum to lower dietary fat intake in a multiethnic population with low literacy skills. *J Nutr Educ* 1997; 29:215-223.

88. Stone EJ, Pearson TA, **Fortmann SP**, McKinlay JB. Community-based prevention trials: Challenges and directions for public health practice, policy, and research. *Ann Epidemiol* 1997; 7 (S7): S113-S120.

89. Winkleby MA, Howard-Pitney B, Albright CA, Bruce B, Kraemer HC, **Fortmann SP**. Predicting achievement of a low fat diet: A nutrition intervention for adults with low literacy skills *Prev Med* 1997; 26: 874-882.

90. Howard-Pitney B, Winkleby MA, Albright CL, Bruce B, **Fortmann SP**. The Stanford Nutrition Action Program: a dietary fat intervention for low literate adults. *Am J Public Health*1997; 87(12): 1971-1976.

91. Schooler C, Farquhar JW, **Fortmann SP**, Flora J. Synthesis of findings and issues from community prevention trials. *Annals of Epidemiology*, 1997: 7(7 Supplement); S54-S68.

92. Tuomilehto J, for the WHO MONICA Project. Changes in cigarette smoking among adults in 35 populations in the mid-1980s. *Tobacco Control* 1998; 7:14-21.

93. Ribisl KM, Winkleby MA, **Fortmann SP**, Flora JA. The interplay of socioeconomic status and ethnicity on Hispanic and White men's cardiovascular disease risk and health communication patterns. *Health Education Research* 1998; 13: 407-417.

94. Davis SK, Ahn DK, **Fortmann SP**, Farquhar JW. Determinants of cholesterol screening and treatment patterns: insights for decision-makers. *Am J Prev Med* 1998;15(3):178-186.

95. Davis SK, **Fortmann SP**. Policy implications of health outcomes associated with level of cardiovascular disease risk reduction knowledge: findings from a population-based cohort. *CVD Prevention* 1998;1:138-146.

96. Greeno CG, Jackson C, Williams EL, **Fortmann SP**. The effect of perceived control over eating on the life satisfaction of women and men: results from a community sample. *Int J Eat Disord* 1998; 24**:** 415-419.

97. Altman DG, Wheelis AY, McFarlane M, Lee H, **Fortmann SP**. The relationship between tobacco access and use among adolescents: A four community study. *Social Science and Medicine* 1999; 48:759-775.

98. Daughton DM, **Fortmann SP**, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Rennard SI. The smoking cessation efficacy of varying doses of nicotine patch delivery systems four to five years post quit day. *Preventive Medicine* 1999; 28: 113-118.

99. Killen JD, **Fortmann SP**, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? *Exp Clin Psychopharm* 1999; 7(3): 226-33.

100. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, Broughton J, **Fortmann SP**, Leischow SJ, McKenna J, Rennard SI, Wadland W, Heatley S. Are higher doses of nicotine replacement more effective? Nicotine Tobacco Res 1999;1: 169-174.

101. Stamler J, **Fortmann SP**, Levy RI, Prineas RJ, Tell G. Primordial prevention of cardiovascular disease risk factors: panel summary. *Prev Med* 1999; 29: S130-S135.

102. Howard-Pitney B, Killen JD, **Fortmann SP**. Quitting Chew: Results from a randomized trial using nicotine patches. *Exp Clin Psychopharm* 1999; 7: 362-371.

103. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, **Fortmann S**, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto J for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. *Lancet* 2000; 355:675-687.

104. Gardner CD, Winkleby MA, **Fortmann SP**. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1998–1994). *Am J Cardiol* 2000; 86: 299-304.

105. **Fortmann SP**, Varady AN. Effects of a community-wide health education program on cardiovascular disease morbidity and mortality: The Stanford Five-City Project. *Am J Epidemiol* 2000; 152: 316–323.

106. Gardner CD, Tribble DL, Young DR, Ahn D, **Fortmann SP**. Population frequency distributions of HDL, HDL_2, and HDL_3 cholesterol and apolipoproteins A-I and B in healthy men and women and associations with age, gender, hormonal status and sex hormone use: The Stanford Five-City Project. *Prev Med* 2000; 31: 335-345.

107. Gardner CD, Tribble DL, Young DR, Ahn D, **Fortmann SP**. Associations of HDL, HDL_2, and HDL_3 and apolipoproteins A-I and B with lifestyle factors in healthy women and men: The Stanford Five City Project. *Prev Med* 2000; 31: 346-356.

108. Killen JD, **Fortmann SP**, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A. Nicotine patch and paroxetine for smoking cessation. *J Consult Clin Psych* 2000; 68: 883–889.

109. Cooper R, Cutler J, Desvigne-Nickens P, **Fortmann SP**, Friedman L, Havlik R, Hogelin G, Manolio T, Marler J, McGovern P, Morosco G, Mosca L, Pearson T, Stamler J, Stryer D, Thom T. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the National Conference on CVD Prevention. *Circulation* 2000; 102:3137-3147.

110. Molarius A, Parsons RW, Dobson AJ, Kuulasmaa K, Moltchanov V, Evans A, **Fortmann SP**, Jamrozik KD, Sans S, Tuomilehto J and Puska P for the WHO MONICA Project. Trends in cigarette smoking in 36 populations from the early 1980s to the mid 1990s: Findings from the WHO MONICA Project. *Am J Public Health* 2001; 91:206-212.

111. Howard-Pitney B, **Fortmann SP**, Killen JD. Generalizability of findings from a chewing tobacco cessation clinical trial. *Nicotine Tobacco Res* 2001; 3: 347-352.

112. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, **Fortmann SP**. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. *Kidney International* 2001; 60: 1106-1113.

113. Palaniappan L, Carnethon M, **Fortmann SP**. Heterogeneity in the relationship between ethnicity, body mass index, and fasting insulin. *Diabetes Care* 2002; 25: 1351-1357.

114. Carnethon M, Palaniappan L, Burchfiel C, Brancati F, **Fortmann SP**. Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults: The Atherosclerosis Risk in Communities Study, 1987–1998. *Diabetes Care* 2002; 25: 1358-1364.

115. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, **Fortmann SP**, Franklin, BA, Goldstein LB, Greenland P, Grundy S, Hong Y, Houston Miller N, Lauer RM, Ockene IS, Sacco R, Sallis JF, Smith SC, Stone NJ, Taubert, KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. *Circulation* 2002; 106:388-391.

116. Killen JD, **Fortmann SP**, Kraemer HC, Varady A. Do men outperform women in smoking cessation studies? Maybe - but not by much. *Experimental and Clinical Psychopharmacology* 2002; 10: 295-301.

117. Henriksen L, Flora JA, Feighery EC, **Fortmann SP**. Effects on youth of exposure to retail tobacco advertising. *J Applied Social Psych* 2002; 32: 1771-1789.

118. Henriksen L, **Fortmann SP**. Young adults' opinions of Philip Morris and its television advertising. *Tobacco Control* 2002; 11: 236-240.

119. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, **Fortmann SP**, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers For Disease Control and Prevention and the American Heart Association. *Circulation* 2003; 107:499-511.

120. Killen JD, **Fortmann SP**, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment of nicotine dependence. *Addictive Behaviors* 2003; 28: 461–470

121. Wrone EM, Carnethon MR, Palaniappan L, **Fortmann SP**. Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003; 41:580-587.

122. Pearson TA, Bazzare T, Daniels SR, Fair JM, **Fortmann SP**, Franklin BA, Goldstein LB, Hong Y, Lauer RM, Mensah GA, Sallis JF, Smith S, Stone JNJ, Taubert KA. AHA Guide for improving cardiovascular health at the community level. A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. *Circulation* 2003; 107: 645-651.

123. Carnethon MR, Kinder LS, Fair JM, Stafford RS, **Fortmann SP**. Symptoms of depression as a risk factor for incident diabetes: Findings from the National Health and Nutrition Examination Epidemiologic Follow-Up Study, 1971-1992. *Am J Epidemiol* 2003;158:416–423.

124. Palaniappan L, Carnethon, MR, **Fortmann SP**. Association between microalbuminuria and the metabolic syndrome: NHANES III. *Am J Hypertension*. 2003; 16:952-958.

125. Hughes JR, Callas PW, High Dose Study Group [in alphabetical order: JO Broughton, **SP Fortmann**, DK Hatsukami, SA Heatley, JR Hughes, DE Jorenby, SJ Leischow, GR Lesmes, E Lichtenstein, JP McKenna, SR Rennard, RLRichmond and WC Wadland] Past alcohol problems do not predict smoking cessation outcomes. *Drug Alcohol Dependence* 2003; 71: 269-273.

126. Luepker RV, Apple FS, Christenson RH, Crow RS, **Fortmann SP**, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P, Tunstall-Pedoe H. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. *Circulation* 2003; 158:1058–1067.

127. Carnethon MR, **Fortmann SP**, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: The Atherosclerosis Risk in Communities Study, 1987 – 1998. *Am J Epidemiol* 2003; 158:1058-1067.

128. Palaniappan L, Carnethon MR, Wang Y, Hanley AJG, **Fortmann SP**, Haffner SM, Wagenknecht L. Predictors of incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. *Diabetes Care* 2004; 27: 788-793.

129. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, **Fortmann SP**. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrology* 2004; 15: 420-426.

130. Kinder LS, Carnethon MR, Palaniappan LP, King AC, **Fortmann SP**. Depression and the metabolic syndrome in young adults: Findings from the Third National Health and Nutrition Examination Survey. *Psychosomatic Med* 2004; 66: 316-322.

131. Palaniappan L, Wang J, **Fortmann SP**. Coronary heart disease mortality for six ethnic groups in California 1990 – 2000. *Ann Epidemiol* 2004; 14: 499-506.

132. Henriksen L, Feighery EC, Schleicher NC, Haladjian HH, **Fortmann SP**. Reaching youth at the point of sale: Cigarette marketing is more prevalent in stores where adolescents shop frequently. *Tobacco Control* 2004; 13: 315-318.

133. Henriksen L, Feighery EC, Wang Y, **Fortmann SP**. Association of retail tobacco marketing with adolescent smoking. *Am J Public Health* 2004; 94: 2081-2083.

134. **Fortmann SP,** Ford E, Criqui MH, Folsom AR, Harris TB, Hong Y, Pearson TA, Siscovick D, Vinicor F, Wilson PF; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to clinical and public health practice: report from the population science discussion group. *Circulation* 2004; 110: e554-9.

135. Jamison, RL, Hartigan P, Gaziano JM, **Fortmann SP**, Goldfarb DS, Haroldson JA, Kaufman J, Lavori P, McCully KS, Robinson K. Design and statistical issues in the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) Study. *Clin Trials* 2004; 1: 451-460

136. Henriksen L, Dauphinee AL, Wang Y, **Fortmann SP**. Industry-sponsored anti-smoking ads and adolescent reactance: Test of a boomerang effect. *Tobacco Control* 2006; 15:13-18.

137. Go AS, Iribarren C, Chandra M, Lathon PV, **Fortmann SP**, Quertermous, T, Hlatky MA for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Statin and ß-blocker therapy and the initial presentation of Coronary Heart Disease. *Ann Intern Med* 2006; 144: 229-238.

138. Madan A, Palaniappan L, Urizar G, Wang Y, **Fortmann SP**, Gould JB Sociocultural factors that affect pregnancy outcomes in two dissimilar immigrant groups in the United States. *J Pediatr* 2006; 148: 341-346.

139. Killen JD, **Fortmann SP**, Murphy GM, Hayward C, Arredondo CJ, Cromp D, Celio M, Abe L, Wang Y, Schatzberg AF. Extended treatment with bupropion for cigarette smoking cessation. *J Consult Clin Psych* 2006; 74: 286-294.

140. Taylor-Piliae RE, Norton LC, Haskell WL, Mahbouda MH, Fair JM, Iribarren C, Hlatky MA, Go AS, **Fortmann SP**. Validation of a new brief physical activity survey among men and women aged 60-69 years. *Am J Epidemiol*. 2006 Sep 15;164(6):598-606.

141. Feighery EC, Henriksen L, Wang Y, Schleicher NC, **Fortmann SP**. An evaluation of four measures of adolescents' exposure to cigarette marketing in stores. *Nic Tobac Res* 2006; 8: 751-759.

142. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, Quertermous T, Hlatky MH, **Fortmann SP**. Metabolic syndrome and early-onset coronary artery disease: Is the whole greater than it's parts?. *J Am Coll Cardiol* 2006; 48: 1800-1807.

143. Hurtz SQ, Henriksen L, Wang J, Feighery EC, **Fortmann SP**. The relationship between exposure to alcohol advertising in stores, owning alcohol promotional items, and adolescent alcohol use. *Alcohol & Alcoholism* 2007; 42:143-149. Epub 2007 Jan 11 (PMID: 17218364).

144. Iribarren C, Husson G, Go AS, Lo JC, Fair JM, Rubin GD, Hlatky MA, **Fortmann SP**. Plasma leptin levels and coronary artery calcification in older adults. *J Clin Endocrinol Metab* 2007; 92: 729-32.

145. Kennedy BS, **Fortmann SP**, Winkleby MA, Stafford RS. Elective and isolated carotid endarterectomy: health disparities in utilization and outcomes, but not readmission. *J Nat Med Assoc* 2007; 99:480-488.

146. Taylor-Piliae RE, Haskell WL, IribarrenC, Norton LC, Mahbouda MH, Fair JM, Hlatky MA, Go AS, **Fortmann SP**. Clinical utility of the Stanford Brief Activity Survey in men

and women with early-onset coronary artery disease. *J Cardioplum Rehab Prev* 2007; 27:227-232.

147. Fair JM, Kiazand A, Varady AN, Mahbouba MH, Norton L, Rubin G, Iribarren C, Go AS, **Fortmann SP**. Ethnic differences in coronary artery calcium in a healthy cohort aged 60 to 69 years. *Am J Cardiol* 2007;100:981–985.

148. Ardigo D, Assimes T, **Fortmann SP**, Go AS, Hlatky M, Hytopoulos E, Iribarren C, Tsao PS, Tabibiazar R, Quertermous T. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. *Physiol Genomics* 2007; 31: 402-409 [first published Aug 14, 2007; doi:10.1152/physiolgenomics.00104.2007; PMID: 17698927].

149. Hlatky MA, Quertermous T, Myers RM, Boothroyd DB, **Fortmann SP**, Iribarren C, Tabor HK, Assimes TL, Tibshirani RJ, Go AS. Polymorphisms in Hypoxia Inducible Factor 1 and the Initial Clinical Presentation of Coronary Disease. *Am Heart J* 2007; 154: 1035-1042.

150. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, Southwick A, Myers RM, Iribarren C, **Fortmann SP**, Go AS, for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. *Am Heart J* 2007; 154:1043-1051).

151. Knowles JW, Wang H, Itakura H, Southwick A, Myers RM, Iribarren C, **Fortmann SP**, Quertermous T, Hlatky MA. Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. *Am Heart J* 2007; 154: 1052-1058.

152. Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, **Fortmann SP**, Quertermous T, Hlatky MA for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina? *Am Heart J* 2007; 154: 1059-1064.

153. Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, Grove ML, Tabor HK, Southwick A, Tabibiazar R, Sidney S, Boerwinkle E, Go AS, Iribarren C, Hlatky MA, **Fortmann SP**, Myers RM, Kuhn H, Risch N, Quertermous T. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. *Atherosclerosis* 2008; 198: 136-144.[2007; Oct 22; Epub ahead of print; PMID: 17959182].

154. Henriksen L, Schleicher NC, Feighery EC, **Fortmann SP**. Receptivity to alcohol marketing predicts drinking initiation. *J Adolesc Health* 2008; 42: 28–35. PMCID: [PMC2175037]

155. Knowles JW, Assimes TL, Boerwinkle E, **Fortmann SP**, Go A, Grove M, Hlatky M, Iribarren C, Li J, Myers R, Risch N, Sidney S, Southwick A, Volcik KA, Quertermous T. Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD. BMC Medical Genetics 2008; **9**:23 (doi:10.1186/1471-2350-9-23); e-published 2 April 2008 (http://www.biomedcentral.com/1471-2350/9/23).

156. Burt JR, Iribarren C, Fair JM, Norton LC, Mahbouba M, Rubin GD, Hlatky MA, Go AS, **Fortmann SP**; for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Incidental findings on cardiac multidetector row computed tomography among healthy older adults: Prevalence and clinical correlates. *Arch Intern Med* 2008;168:756-761.

157. **Fortmann SP**. Invited Commentary. Race, ethnicity, biology, and medical research: A modest proposal. *Curr Cardiovasc Risk Reports* 2008; 2: 167–168.

158. Killen JD, **Fortmann SP**, Schatzberg AF, Arredondo C, Murphy G, Hayward C, Celio M, Cromp D, Fong D, Pandurangi M. Extended cognitive behavior therapy for cigarette smoking cessation. *Addiction* 2008; 103: 1381–1390.

159. Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, **Fortmann SP**, Franklin BA, Gillman MW, Lewis CE, Poston WC 2nd, Stevens J, Hong Y; American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). *Circulation*. 2008 Jul 22;118(4):428-64. Epub 2008 Jun 30.

160. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Lic J, Fair JM, Rubin GD, Sidney S, **Fortmann SP**, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE Study. *Hum Mol Genet* 2008;17:2320-2328.

161. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, Tabor HK, Hartiala J, Allayee H, Grove ML, Tabibiazar R, Sidney S, **Fortmann SP**, Go A, Hlatky MA, Iribarren C, Boerwinkle E, Myers R, Risch N, Quertermous T. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. *Hum Genet* 2008; 123: 399-408.

162. Terashima M, Nguyen PK, Rubin GD, Iribarren C, Courtney BK, Go AS, **Fortmann SP**, McConnell MV. Impaired coronary vasodilation by magnetic resonance angiography is associated with advanced coronary artery calcification. *J. Am. Coll. Cardiol. Img*. 2008;1;167-173.

163. Henriksen L, Feighery EC, Schleicher NC, Cowling DW, Kline RS, **Fortmann SP**. Is adolescent smoking related to the density and proximity of tobacco outlets and retail cigarette advertising near schools? *Prev Med*. 2008 Aug;47(2):210-4 [Epub 2008 Apr 29].

164. Iribarren C, Hlatky MA, Chandra M, Fair JM, Rubin GE, Go AS, Burt JR, **Fortmann SP** for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Incidental pulmonary nodules on cardiac computed tomography: prognosis and use. *Am J Med* 2008; 121: 989-996.

165. Lee KL, **Fortmann SP**, Fair JM, Iribarren C, Rubin GD, Varady A, Go AS, Quertermous T, Hlatky MA. Insulin resistance independently predicts the progression of coronary artery calcification. *Am Heart J* 2009;157:939-45.

166. Dallongeville J, Iribarren C, Ferrières J, Lyon L, Evans A, Go AS, Arveiler D, **Fortmann SP**, Ducimetière P, Hlatky MA, Amouyel P, Southwick A, Quertermous T Meirhaeghe A. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. *PPAR Research* vol. 2009, Article ID 543746, 11 pages, 2009 (doi: 10.1155/2009/543746)[http://www.hindawi.com/journals/ppar/2009/543746.html].

167. Sydow K, **Fortmann SP**, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS. Distribution of asymmetric dimethylarginine among 980 healthy older adults of different ethnicities. *Clin Chem* 2010; 56: 111-120 [epub ahead of print 2009 Nov 5] PMID: 19892843

168. Taylor-Piliae RE, Fair JM, Haskell WL, Varady AN, Iribarren C, Hlatky MA, Go AS, **Fortmann SP**. Validation of the Stanford Brief Activity Survey: Examining psychological factors and physical activity levels in older adults. *J Phys Activity Heath* 2010; 7:87-94.

169. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nature Genetics* 2010; 42:441–447 [April 25, epub ahead of print; PMID 20418890; *doi:10.1038/ng.571*].

170. Bailey, SR, Fong, DM, Bryson, SW, **Fortmann, SP**, Killen, JD. Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy. *Journal of Substance Abuse Treatment* 2010; 39:150-156. [Jul 2: epub ahead of print; PMID 20598833]

171. Henriksen L, Schleicher NC, Feighery EC, **Fortmann SP**. A longitudinal study of exposure to retail cigarette advertising and smoking initiation. *Pediatrics* 2010; 19 Jul [epub ahead of print; PMID 20643725].

172. Killen JD, **Fortmann SP**, Murphy G, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. *Addiction* 2010; 105:1660-1668 [PMID: 20707784].

173. Assimes TL, Holm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, et al. (140 total authors). Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. *J Am Coll Cardiol* 2010; 56: 1552-1563. [PMID: 20933357]

174. Terashima M, Nguyen PK, Rubin GD, Meyer CH, Shimakawa A, Nishimura DG, Ehara S, Iribarren C, Courtney BK, Go AS, Hlatky MA, **Fortmann SP**, McConnell MV. Right coronary wall CMR in the older asymptomatic ADVANCE cohort: Positive remodeling and associations with type 2 diabetes and coronary calcium. *Journal of Cardiovascular Magnetic Resonance* 2010, **12**:75 [doi:10.1186/1532-429X-12-75]

175. Palaniappan LP, Wong EC, Shin JJ, **Fortmann SP**, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. *Int J Obes (Lond)*. Mar 2011; 35(3):393-400. [PMC: 2989340] [PMID 20680014] [Epub 3 August 2010; doi: 10.1038/ijo.2010.152]

176. Sarginson JE, Killen JD, Lazzeroni LC, **Fortmann SP**, Ryan HS, Schatzberg AF, Murphy GM. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *Am J Med Genet B: Neuropsych Genet* 2011; 156(3):275-84. [Epub 2011 Jan 25] [PMID: 21268243].

177. Taylor-Piliae RE, Fair JM, Varady AN, Hlatky MA, Norton LC, Iribarren C, Go AS, **Fortmann SP**. Ankle brachial index screening in asymptomatic older adults. *Am Heart J* 2011; 161: 979-985 [PMID: 21570532].

178. Banerjee D, Wong EC, Shin J, **Fortmann SP**, Palaniappan L. Racial and Ethnic Variation in Lipoprotein(a) levels among Asian Indian and Chinese Patients. *J Lipids* 2011; vol. 2011, Article ID 291954, 6 pages, doi:10.1155/2011/291954. [PMID: 21660301]

179. Wang EJ, Wong EC, Dixit AA, **Fortmann SP**, Linde RB, Palaniappan LP. Type 2 diabetes: Identifying high risk Asian American subgroups in a clinical population. *Diabetes Research and Clinical Practice* 2011; 93:248-254 (epub ahead of print, June 10; doi: 10.1016/j.diabres.2011.05.025) [PMID 21665315].

180. Nguyen PK, Terashima M, Fair JM, Varady A, Taylor-Piliae RE, Iribarren I, Go AS, Haskell WL, **Fortmann SP**, McConnell MV. Physical activity in older subjects is

associated with increased coronary vasodilation in the ADVANCE Study. *J Am Coll Cardiol Cardiovasc Imaging* 2011; 4 (6): 622-9. [PMID: 21679897]

181. Henriksen L, Schleicher NC, Dauphineé A, **Fortmann SP**. Targeted advertising, promotion, and price for menthol cigarettes in California high school neighborhoods. *Nicotine Tobacco Res* 2011; (Epub ahead of print, 24 June 2011: doi 10.1093/ntr/ntr122). [PMID: 21705460]

182. Lee KK, **Fortmann SP**, Varady A, Fair JM, Go AS, Quertermous T, Hlatky MA, Iribarren C. Racial variation in lipoprotein-associated phospholipase A_2 in older adults. *BMC Cardiovasc Disorders* 2011; 11 (1): 38 (doi:10.1186/1471-2261-11-38). [PMID: 21714927]

183. Bansal N, Hsu C, Chandra M, Iribarren C, **Fortmann SP**, Hlatky MA, Go AS. Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study. *BioMed Central Nephrology* 2011; 12:44 (doi:10.1186/1471-2369-12-44). [PMID tba]

184. Go AS, Bansal N, Chandra M, Lathon PV, **Fortmann SP**, Iribarren C, Hsu C, Hlatky MA, ADVANCE Study Investigators. Chronic kidney disease and risk of presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. *J Am Coll Cardiol* 2011; 58: 1600-07. [PMID 21958887]

185. Elias-Smale SE, Fair JM, Varady AN, Iribarren C, Go AS, Hlatky MA, Rubin GD, Witteman JC, **Fortmann SP**. Is elevated heart rate related to severity or progression of coronary atherosclerosis in healthy older adults? *Am Heart J* (submitted July 2010).

186. Henriksen L, Schleicher NC, Winn L, Hrushow A, **Fortmann SP**. Impact of banning tobacco sales in pharmacies on distribution of tobacco outlets. *Am J Prev Med* (submitted November 2010).

187. Ambrosius WT, Polonsky T, Greenland P, Goff DC, Perdue LH, **Fortmann SP**, Margolis KL, Pajeweski NM. Design of the Value of Imaging in Enhancing the Wellness (VIEW) of Your Heart Trial and the Impact of Uncertainty on Power. Clinical Trials (submitted August 2011).

2. Non-peer-reviewed articles

1. **Fortmann SP**. Abortion and medicine. The *Pharos* of Alpha Omega Alpha 1975;38:25-29.

2. Sallis JF, Hill RD, **Fortmann SP**, Flora JA. Heart health behavior change at the worksite: Cardiovascular risk reduction. *Progress in Behavior Modification* 1986;20:161-97.

3. Frank E, **Fortmann SP**, Causey DD. The impact of smoking cessation on cardiovascular risk. *Modern Medicine* 1994;62:3-10.

4. **Fortmann SP**. Smoking: No time for complacency [Editorial]. *Cardiovascular Risk Factors* 1996; 6:123-125.

5. **Fortmann SP**, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle [Editorial]. *Circulation* 1997; 95: 295-296.

6. **Fortmann SP**. A refresher on the management of common lipid disorders. *The Chronicle of Cardiovascular and Internal Medicine* 1997 (December); 1 (2): 11-12.

7. **Fortmann SP**. Race, ethnicity, biology, and medical research: A modest proposal [Invited Commentary]. *Curr Cardiovasc Risk Reports* (accepted December 2007)

3. Book

Fortmann SP, Breitrose PE. *The Blood Pressure Book*. Palo Alto, CA: Bull Publishing Company, 1996, 2001 (2nd Edition), 2006 (3rd Edition).
Third Edition translated and issued in Spanish in 2006, *Libro de la presión sanguínea*.

4. Book Chapters

1. Hulley SB, **Fortmann SP**. Clinical trials of changing behavior to prevent cardiovascular disease. In Weiss SM, Herd JA, Fox BH, (eds). *Perspectives in Behavioral Medicine*. New York: Academic Press, 1980:89-98.
2. Farquhar JW, **Fortmann SP**, Wood PD, Haskell WL. Community studies of cardiovascular disease prevention. In Kaplan NM, Stamler J, (eds). *Prevention of Coronary Heart Disease*. Philadelphia: WB Saunders Co., 1983:l70-l8l.
3. **Fortmann SP**. Nutritional factors in chronic disease. In: Haller EW, Cotton GE, (eds). *Proceedings of the Conference on Nutrition in the Young and the Elderly*. Lexington, MA: The Collamore Press, 1983:l73-l88.
4. Farquhar JW, **Fortmann SP**, Maccoby N, Wood PD, Haskell WL, Taylor CB, et al. The Stanford Five-City Project: An overview. In Matarazzo JD, Miller NE, Weiss SM, Herd JA, Weiss SM (eds). *Behavioral Health: A Handbook of Health Enhancement and Disease Prevention*. Silver Spring, MD: John Wiley & Sons, Inc; 1984: ll54-65.
5. Taylor CB, **Fortmann SP**. Essential hypertension. In Dorfman W, Cristofar L (eds). *Psychosomatic Illness Review*. New York: Macmillan Publishing Company, 1985: 90-106.
6. Rudd P, Price MG, Graham LE, **Fortmann SP**, Beilstein B, Tarbell S, Bacchetti P. Impact of hypertensive labeling on worker absenteeism and psychoscocial dysfunction. In Rosenfeld JB, Silverberg DS, Viskoper R (eds). *Hypertension Control in the Community*. London: John Libby & Co., Ltd., 1985: 62-66.
7. Farquhar JW, **Fortmann SP**. Problems with implementing public intervention strategies. In Lundgarde F (ed): Proceedings of the First Ernhold Lundstrom Symposium: *Genetic Susceptibility to Environmental Factors - a Challenge for Public Intervention*. Stockholm, Sweden: Almqvist & Wiskell, 1988.
8. Committee on Criteria and Methods of the Council on Epidemiology, American Heart Association. *Annotated bibliography of epidemiological methods of cardiovascular research*. Dallas, TX: American Heart Association, 1989. [Dr. Fortmann chaired the committee and edited the monograph]
9. Farquhar JW, **Fortmann SP**, Flora JA, Maccoby N. Methods of communication to influence behaviour. In Holland WW, Detels R, Knox G, (eds). *Oxford Textbook of Public Health*. New York: Oxford University Press, 1991:331-344.
10. **Fortmann SP**, Maron DJ. Disorders of lipid metabolism. In Dale, DC, Federman DD (eds): *Scientific American Medicine* 1991; Section 9, Subsection II: 1-24. [Revised and reissued, 1993, 1996, 1998]
11. Farquhar JW, **Fortmann SP**. Phases for developing community trials: Lessons for control of alcohol problems from research in cardiovascular disease, cancer, and adolescent health.

In Holder HD, Howard JM (eds). *Community Prevention Trials for Alcohol Problems: Methodological Issues*. Westport, CT: Praeger Publishers, 1992: 59-75

12. Flora JA, Jatulis D, Jackson C, **Fortmann SP**. The Stanford Five-City Heart Disease Prevention Project. In Backer TE, Rogers E (eds). *Organizational aspects of health communication campaigns: What works?* Newbury Park, CA: Sage Publications, 1993: 101-128.
13. **Fortmann SP**. Controlling high blood pressure with exercise. In: *Fresh Start: The Stanford Medical School Health and Fitness Program*. San Francisco, CA: KQED Books and Video, 1996: 189-199.
14. **Fortmann SP**, Shane B, Motulsky A. Summary and future directions for epidemiological, preventive, and basic research. In Robinson K (ed). *Homocysteine and Vascular Disease*. Dordrecht, The Netherlands and Norwell, MA: Kluwer Academic Publishers, 2000: 431-436.
15. Farquhar JW, **Fortmann SP.** Community-based Health Promotion. In Ahrens W, Pigeot I (eds.) *Handbook of Epidemiology*. New York: Springer, 2005: 1305-1323.

5. Recent Abstracts (6 of 75)

1. Bailey, S.R., Fong, D.M., Bryson, S.W., Fortmann, S.P., & Killen, J.D. Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy. Society for Research on Nicotine & Tobacco, 14th Annual Scientific Meeting: Portland, OR. February 2008.
2. Wong E, Lauderdale DS, **Fortmann SP**, Palaniappan LP. Heterogeneity in Cardiovascular Risk Factors Among Asian American Subgroups. Presented at the 48th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, Colorado Springs, CO, March 12-15, 2008.
3. Palaniappan, L, Wong EC, Shin J, **Fortmann SP**, Lauderdale DS. Asian Americans Have Greater Prevalence of Metabolic Syndrome Despite Lower BMI. Presented at American Heart Association 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, Palm Harbor, FL, 11-14 March 2009.
4. Dauphinee AL, Schleicher NC, **Fortmann SP**, Henriksen L. Menthol Cigarettes Cost Less Near High Schools with More African American Students. Presented at the Society for Research on Nicotine and Tobacco, Toronto, Canada, 16-19 February 2011.
5. Henriksen L, Schleicher NC, Winn LE, Hrushow A, **Fortmann SP**. Impact of Banning Tobacco Sales in Pharmacies on the Distribution of Tobacco Outlets: San Francisco, CA. Presented at the Society for Research on Nicotine and Tobacco, Toronto, Canada, 16-19 February 2011.
6. Reynolds K, Adams KF, Cassidy-Bushrow AE, **Fortmann SP**, Go AS, et al. Nine-Year Trends in the Annual Rate of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN), 2000-2008. Presented at the Annual Meeting of the American Heart Association Council on Epidemiology and Prevention; Atlanta, GA; 24-25 March 2011.